Significant geographic variations in practice and adjusted mortality following fibrinolysis persist despite recent guidelines. These findings have important implications in the design and interpretation of international studies, identify under- and over-utilized therapies, and support further study of treatments with marked worldwide variations.

Learning Objectives After completing this course, the reader will be able to: Assess the rationale behind using i.p. chemotherapy for epithelial ovarian cancer patients and critically evauate the data supporting its use. Interpret the argument that i.p. chemotherapy cannot be accepted as standard of care for first‐line systemic treatment of advanced ovarian carcinoma. Determine which epithelial ovarian cancer patients may be appropriate for i.p. chemotherapy. Avoid and/or manage the toxicities observed with i.p. chemotherapy. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at http://CME.TheOncologist.com The CME activity for this article consists of material from both “Intraperitoneal Chemotherapy for Women with Epithelial Ovarian Cancer” (Trimble et al.) and “Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View” (Vergote et al.).

No abstract

No abstract

No abstract